Neoprobe Receives FDA Acceptance of Lymphoseek New Drug Application

by Matthew Kennedy, Benzinga Staff Writer

October 19, 2011 5:38 PM | 11 seconds read | Make a Comment

Neoprobe Corporation (NYSE Amex: NEOP) today announced that its New Drug Application for Lymphoseek has been accepted for review by the U.S. Food and Drug Administration. Neoprobe submitted the Lymphoseek NDA on August 10, 2011.

Market News and Data brought to you by Benzinga APIs

Posted In: News FDA

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Neoprobe Receives FDA Acceptance of Lymphoseek New Drug Application